❌

Normal view

Received — 26 March 2026 ⏭ Nature Biotechnology - Issue - nature.com science feeds

Nature Biotechnology - Issue - nature.com science feeds
Sustained nitric oxide production by engineered <i>E. coli</i> remodels the tumor microenvironment and potentiates immunotherapy Shuyu Xu · Tianjiao Zhang · Yang Song · Mengxin Wang · Ruiqi Wu · Mofan Li · Haonan Wang · Xinxin Xie · Qingfeng Chen · Xiaotu Ma · Xiaolong Liang
Nature Biotechnology, Published online: 18 March 2026; doi:10.1038/s41587-026-03054-ySolid tumors are sensitized to anti‑PD‑L1 immunotherapy by engineered E. coli to produce nitric oxide.
18 March 2026 at 08:00

Sustained nitric oxide production by engineered <i>E. coli</i> remodels the tumor microenvironment and potentiates immunotherapy

Nature Biotechnology - Issue - nature.com science feeds

By: Shuyu Xu · Tianjiao Zhang · Yang Song · Mengxin Wang · Ruiqi Wu · Mofan Li · Haonan Wang · Xinxin Xie · Qingfeng Chen · Xiaotu Ma · Xiaolong Liang

18 March 2026 at 08:00

Nature Biotechnology, Published online: 18 March 2026; doi:10.1038/s41587-026-03054-y

Solid tumors are sensitized to anti‑PD‑L1 immunotherapy by engineered E. coli to produce nitric oxide.